Myocardial Fibrosis – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Myocardial Fibrosis – Pipeline Review, H2 2019’, provides an overview of the Myocardial Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis

– The report reviews pipeline therapeutics for Myocardial Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Myocardial Fibrosis therapeutics and enlists all their major and minor projects

– The report assesses Myocardial Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Myocardial Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Myocardial Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myocardial Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ember Therapeutics Inc (Inactive)

Evotec SE

Galectin Therapeutics Inc

Haya Therapeutics

Invivosciences Inc

Lead Discovery Center GmbH

Liminal BioSciences Inc

MandalMed Inc

Merck & Co Inc

NovoMedix LLC

Palatin Technologies Inc

Pharmaxis Ltd

TRACON Pharmaceuticals Inc

Vectus Biosystems Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myocardial Fibrosis - Overview

Myocardial Fibrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myocardial Fibrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myocardial Fibrosis - Companies Involved in Therapeutics Development

Ember Therapeutics Inc (Inactive)

Evotec SE

Galectin Therapeutics Inc

Haya Therapeutics

Invivosciences Inc

Lead Discovery Center GmbH

Liminal BioSciences Inc

MandalMed Inc

Merck & Co Inc

NovoMedix LLC

Palatin Technologies Inc

Pharmaxis Ltd

TRACON Pharmaceuticals Inc

Vectus Biosystems Ltd

Myocardial Fibrosis - Drug Profiles

Antisense Oligonucleotides for Myocardial Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belapectin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMP-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Tissue Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GYY-4137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-922 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-5028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PN1-Ab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5153A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5338K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXS-5382A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPI-2049 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRC-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-0004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myocardial Fibrosis - Dormant Projects

Myocardial Fibrosis - Discontinued Products

Myocardial Fibrosis - Product Development Milestones

Featured News & Press Releases

Oct 08, 2019: Publication that demonstrates reversal of established fibrosis in a preclinical model of cardiac fibrosis by VIP

Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Myocardial Fibrosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Myocardial Fibrosis – Pipeline by Ember Therapeutics Inc (Inactive), H2 2019

Myocardial Fibrosis – Pipeline by Evotec SE, H2 2019

Myocardial Fibrosis – Pipeline by Galectin Therapeutics Inc, H2 2019

Myocardial Fibrosis – Pipeline by Haya Therapeutics, H2 2019

Myocardial Fibrosis – Pipeline by Invivosciences Inc, H2 2019

Myocardial Fibrosis – Pipeline by Lead Discovery Center GmbH, H2 2019

Myocardial Fibrosis – Pipeline by Liminal BioSciences Inc, H2 2019

Myocardial Fibrosis – Pipeline by MandalMed Inc, H2 2019

Myocardial Fibrosis – Pipeline by Merck & Co Inc, H2 2019

Myocardial Fibrosis – Pipeline by NovoMedix LLC, H2 2019

Myocardial Fibrosis – Pipeline by Palatin Technologies Inc, H2 2019

Myocardial Fibrosis – Pipeline by Pharmaxis Ltd, H2 2019

Myocardial Fibrosis – Pipeline by TRACON Pharmaceuticals Inc, H2 2019

Myocardial Fibrosis – Pipeline by Vectus Biosystems Ltd, H2 2019

Myocardial Fibrosis – Dormant Projects, H2 2019

Myocardial Fibrosis – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Myocardial Fibrosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports